Výsledky vyhledávání - "Hematologic Diseases/chemically induced"

Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis:a European expert consensus

Autor: Wolf-Henning Boehncke, Lars Iversen, J. Barker, Richard B. Warren, Kristian Reich, Luigi Naldi, P.C.M. van de Kerkhof, Brian Kirby, Adrian Tanew, Ulrich Mrowietz

Publikováno v: Mrowietz, U, Barker, J, Boehncke, W-H, Iversen, L, Kirby, B, Naldi, L, Reich, K, Tanew, A, van de Kerkhof, P C M & Warren, R B 2018, ' Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis : a European expert consensus ', Journal of the European Academy of Dermatology and Venereology, vol. 32 Suppl 3, pp. 3-14 . https://doi.org/10.1111/jdv.15218
Journal of the European Academy of Dermatology and Venereology, Vol. 32 Suppl 3 (2018) pp. 3-14
JEADV : Journal of the European Academy of Dermatology and Venereology, 32, 3-14
JEADV : Journal of the European Academy of Dermatology and Venereology, 32, pp. 3-14
Mrowietz, U, Barker, J, Boehncke, W-H, Iversen, L, Kirby, B, Naldi, L, Reich, K, Tanew, A, van de Kerkhof, P C M & Warren, R B 2018, ' Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis : a European expert consensus ', Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 32, no. S3, pp. 3-14 . https://doi.org/10.1111/jdv.15218

Fumaric acid esters (FAEs) are a group of small molecules that were first investigated for the treatment of psoriasis in 1959. The first fumarate-based drug - Fumaderm® - was approved in Germany in 1994 for severe psoriasis and then in 2008, the lab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f721758039fbc3c7538f577eb77ac0
https://pure.au.dk/portal/da/publications/clinical-use-of-dimethyl-fumarate-in-moderatetosevere-plaquetype-psoriasis(2193ea4f-9c11-463e-9c7d-988256893f70).html

Zobrazit plný text záznamu

A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial

Autor: Leyvraz, S., Pampallona, S., Martinelli, G., Ploner, F., Perey, L., Aversa, S., Peters, S., Brunsvig, P., Montes, A., Lange, A., Yilmaz, U., Rosti, G., Marrow, Transplantation

Publikováno v: Journal of the National Cancer Institute, vol. 100, no. 8, pp. 533-541

BACKGROUND: The dose intensity of chemotherapy can be increased to the highest possible level by early administration of multiple and sequential high-dose cycles supported by transfusion with peripheral blood progenitor cells (PBPCs). A randomized tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94d9825381050dae08a1ce9fb3198bf
https://doi.org/10.1093/jnci/djn088

Zobrazit plný text záznamu

Sorafenib in patients with refractory or recurrent multiple myeloma

Autor: Yordanova, Anna, Hose, Dirk, Neben, Kai, Witzens-Harig, Mathias, Gütgemann, Ines, Raab, Marc-Steffen, Moehler, Thomas, Goldschmidt, Hartmut, Schmidt-Wolf, Ingo G H

Sorafenib is a small molecular inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor and rapidly accelerated fibrosarcoma kinases, targeting signal transduction a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3848::41e478693efdab0c737f5aef25939174
https://doi.org/10.1002/hon.2043

Zobrazit plný text záznamu

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 19(5)

BACKGROUND: A randomized phase III trial in high-risk breast cancer patients was conducted, to further explore the impact of dose-density in the adjuvant treatment for breast cancer. The safety analysis is presented. PATIENTS AND METHODS: From Octobe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f927f2def92c6c0d8d5521fe00068f
https://pubmed.ncbi.nlm.nih.gov/18042835

Zobrazit plný text záznamu

Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: A pooled analysis of two randomised trials conducted by the hellenic cooperative oncology group

Autor: Koutras, A. K., Fountzilas, G., Dafni, U., Dimopoulos, M. A., Pectasides, D., Klouvas, G., Papakostas, P., Kosmidis, P., Samantas, E., Gogas, H., Briasoulis, E., Vourli, G., Petsas, T., Xiros, N., Haralabos Kalofonos

Publikováno v: Scopus-Elsevier

BACKGROUND: A number of studies have shown that absence of myelotoxicity during chemotherapy is associated with worse outcome for various types of cancer, including carcinoma of the breast. The aim of this study was to determine whether myelosuppress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::51f056da53fa3ccad7e57d34a1ad702b
http://www.scopus.com/inward/record.url?eid=2-s2.0-55749100857&partnerID=MN8TOARS

Zobrazit plný text záznamu

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors

Autor: Hans Gelderblom, Salazar R, Verweij J, Pentheroudakis G, Mj, Jonge, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C

Publikováno v: Europe PubMed Central
Clinical Cancer Research, 9, 4101-4107. American Association for Cancer Research Inc.

PURPOSE: Diflomotecan (BN80915) is an E-ring modified camptothecin analogue that possesses greater lactone stability in plasma compared with other topoisomerase I inhibitors, a potential advantage for antitumor activity. As with other camptothecins,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::509f969795fe2c3edbfab81daf909c39
http://europepmc.org/abstract/med/14519632

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání